Anticoagulation in Pregnant Patients with Thrombophilia

Risk Stratification for Anticoagulation in Pregnancy

Pregnant women with prior history of venous thromboembolism (VTE) should receive postpartum prophylaxis for 6 weeks with prophylactic or intermediate-dose low molecular weight heparin (LMWH) or vitamin K antagonists (INR 2.0-3.0), as recommended by the American College of Chest Physicians 1
Women at moderate to high risk of recurrent VTE should receive antepartum prophylaxis with prophylactic or intermediate-dose LMWH, according to the American College of Chest Physicians guidelines 2
Women with homozygous factor V Leiden or prothrombin 20210A mutation with positive family history for VTE should receive antepartum prophylaxis with prophylactic or intermediate-dose LMWH, as suggested by the American College of Chest Physicians 3
Women receiving long-term vitamin K antagonists should receive adjusted-dose LMWH or 75% of therapeutic dose LMWH throughout pregnancy, as recommended by the American College of Chest Physicians 1

LMWH is strongly recommended over unfractionated heparin (UFH) for prevention and treatment of VTE in pregnant women, according to the American College of Chest Physicians guidelines 5
LMWH offers lower risk of heparin-induced thrombocytopenia compared to UFH, as noted by the American College of Chest Physicians 5
Vitamin K antagonists are contraindicated during pregnancy due to potential teratogenicity, as stated by the American College of Chest Physicians 5

For pregnant women with acute VTE, anticoagulation should continue for at least 6 weeks postpartum with a minimum total duration of 3 months, as recommended by the American College of Chest Physicians 5
LMWH should be discontinued at least 24 hours prior to induction of labor, cesarean section, or expected time of neuraxial anesthesia, according to the American College of Chest Physicians guidelines 2
Anticoagulation can be safely resumed postpartum, even during breastfeeding, as stated by the American College of Chest Physicians 5

Failure to distinguish between thrombophilia types can lead to inadequate management, as noted by the American College of Chest Physicians, with homozygous factor V Leiden and prothrombin 20210A mutations carrying higher risk than other thrombophilias 3
Inadequate duration of therapy can increase the risk of thrombotic events, and postpartum prophylaxis should continue for at least 6 weeks, as recommended by the American College of Chest Physicians 1